Bristol-Myers: Opdivo The Only FDA-approved PD-1 Inhibitor With 4-week Dosing

Bristol-Myers Squibb Co. (BMY) said that the U.S. Food and Drug Administration or FDA has approved a supplemental Biologics License Application or sBLA updating the Opdivo, or nivolumab dosing schedule to include 480 mg infused every four weeks (Q4W) for a majority of approved indications.

from RTT - Biotech http://ift.tt/2HbUjZT
via IFTTT